Outcome of transplantation for acute myelogenous leukemia in children with down syndrome

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 6, 2013, Pages 893-897

  Hitzler, Johann K ^a   He, Wensheng ^b   Doyle, John ^a   Cairo, Mitchell ^c   Camitta, Bruce M ^b   Chan, Ka Wah ^d   Diaz Perez, Miguel A ^e   Fraser, Christopher ^f   Gross, Thomas G ^g   Horan, John T ^h   Kennedy Nasser, Alana A ⁱ   Kitko, Carrie ^j   Kurtzberg, Joanne ^k   Lehmann, Leslie ^l   O'Brien, Tracey ^m   Pulsipher, Michael A ⁿ   Smith, Franklin O ^o   Zhang, Mei Jie ^b   Eapen, Mary ^b   Carpenter, Paul A ^p  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c NEW YORK MEDICAL COLLEGE   (United States)

^d TEXAS TRANSPLANT INSTITUTE   (United States)

^e HOSPITAL INFANTIL UNIVERSITARIO NIÑO JESÚS   (Spain)

^f ROYAL CHILDREN'S HOSPITAL   (Australia)

^g NATIONWIDE CHILDREN S HOSPITAL   (United States)

^h Children's Healthcare of Atlanta at Egleston   (United States)

ⁱ TEXAS CHILDREN S HOSPITAL   (United States)

^j UNIVERSITY OF MICHIGAN   (United States)

^k DUKE UNIVERSITY   (United States)

^l DANA FARBER CANCER INSTITUTE   (United States)

^m SYDNEY CHILDREN'S HOSPITAL   (Australia)

ⁿ PRIMARY CHILDREN'S MEDICAL CENTER   (United States)

^o UNIVERSITY OF CINCINNATI   (United States)

^p USA   (United States)

more..

Author keywords

ALL; AML; Down syndrome; Hematopoietic stem cell transplantation; Pediatric; Relapse; Trisomy 21

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CALCINEURIN INHIBITOR; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHEMORADIOTHERAPY; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN SYNDROME; FEMALE; GRAFT VERSUS HOST REACTION; HAZARD RATIO; HIGH RISK PATIENT; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MALE; MEDICAL RECORD REVIEW; MULTICENTER STUDY; OVERALL SURVIVAL; PRESCHOOL CHILD; SCHOOL CHILD; SURGICAL MORTALITY; TREATMENT FAILURE; TREATMENT OUTCOME; WHOLE BODY RADIATION;

ADOLESCENT; ANTINEOPLASTIC AGENTS; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; DOWN SYNDROME; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; RECURRENCE; REMISSION INDUCTION; RISK FACTORS; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84877892412     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2013.02.017     Document Type: Article

References (23)

1. Horan J.T., Alonzo T.A., Lyman G.H., et al. Impact of disease risk on efficacy of matched related bone marrow transplantation for pediatric acute myeloid leukemia: the Children's Oncology Group. J Clin Oncol 2008 Dec 10, 26:5797-5801.
2. Gibson B.E., Wheatley K., Hann I.M., et al. Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials. Leukemia 2005 Dec, 19:2130-2138.
3. Shaw P.J., Kan F., Woo Ahn K., et al. Outcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched sibling, mismatched related, or matched unrelated donors. Blood 2010, 116:4007-4015.
4. Hasle H., Clemmensen I.H., Mikkelsen M. Risks of leukaemia and solid tumours in individuals with Down's syndrome. Lancet 2000, 355(9199):165-169.
5. Creutzig U., Reinhardt D., Diekamp S., et al. AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity. Leukemia 2005, 19:1355-1360.
6. Kudo K., Kojima S., Tabuchi K., et al. Prospective study of a pirarubicin, intermediate-dose cytarabine, and etoposide regimen in children with down syndrome and acute myeloid leukemia: The Japanese Childhood AML Cooperative Study Group. J Clin Oncol 2007, 25:5442-5447.
7. Sorrell A.D., Alonzo T.A., Hilden J.M., et al. Favorable survival maintained in children who have myeloid leukemia associated with Down syndrome using reduced-dose chemotherapy on Children's Oncology Group trial A2971: A report from the Children's Oncology Group. Cancer 2012, 118:4806-4814.
8. Taub J.W., Ge Y. Down syndrome, drug metabolism and chromosome 21. Pediatr Blood Cancer 2005, 44:33-39.
9. Rubin C.M., Mick R., Johnson F.L. Bone marrow transplantation for the treatment of haematological disorders in Down's syndrome: toxicity and outcome. Bone Marrow Transplant 1996, 18:533-540.
10. Meissner B., Borkhardt A., Dilloo D., et al. Relapse, not regimen-related toxicity, was the major cause of treatment failure in 11 children with Down syndrome undergoing haematopoietic stem cell transplantation for acute leukaemia. Bone Marrow Transplant 2007, 40:945-949.
11. Wheatley K., Burnett A.K., Goldstone A.H., et al. A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. Br J Haematol 1999, 107:69-79.
12. Gamis A.S., Alonzo T.A., Hilden J.M., et al. Outcome of Down syndrome (DS) children with acute myeloid leukemia (AML) or myelodysplasia (MDS) treated with a uniform prospective clinical trial - initial report of the COG Trial A2971. Blood 2006, 108(11):15.
13. Creutzig U., van den Heuvel-Eibrink M.M., Gibson B., et al. Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. Blood 2012, 120:3187-3205.
14. Flowers M.E., Kansu E., Sullivan K.M. Pathophysiology and treatment of graft-versus-host disease. Hematol Oncol Clin North Am 1999, 13:1091-1112. viii-ix.
15. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995, 15:825-828.
16. Klein J., Moeschberger M. Survival analysis: techniques of censored and truncated data 2003, Springer Verlag, New York, NY. 2nd ed.
17. Gamis A.S. Acute myeloid leukemia and Down syndrome evolution of modern therapy-state of the art review. Pediatr Blood Cancer 2005, 44:13-20.
18. Zwaan C.M., Kaspers G.J., Pieters R., et al. Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome. Blood 2002, 99:245-251.
19. Hitzler J.K., Zipursky A. Origins of leukaemia in children with Down syndrome. Nat Rev Cancer 2005, 5:11-20.
20. Lange B.J., Kobrinsky N., Barnard D.R., et al. Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: Children's Cancer Group Studies 2861 and 2891. Blood 1998, 91:608-615.
21. Goleta-Dy A., Dalla Pozza L., Shaw P.J., Stevens M.M. Acute myeloid leukaemia in patients with trisomy 21 (Down syndrome) treated by bone marrow transplantation. J Paediatr Child Health 1994, 30:275-277.
22. Arenson E.B., Forde M.D. Bone marrow transplantation for acute leukemia and Down syndrome: report of a successful case and results of a national survey. J Pediatr 1989, 114:69-72.
23. Taga T., Saito A.M., Kudo K., et al. Clinical characteristics and outcome of refractory/relapsed myeloid leukemia in children with Down syndrome. Blood 2012, 120:1810-1815.